Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
An update from Graft Polymer (UK) PLC ( (GB:SVNS) ) is now available.
Solvonis Therapeutics plc announced its participation in the Mello2025 investor event, where CEO Anthony Tennyson will present and engage with attendees. The company is progressing with its three main R&D programs, including SVNS-001 for severe AUD in Phase 3, SVNS-002 for moderate to severe AUD in Phase 2b planning, and SVNS-SDN-14 for PTSD in preclinical development. These developments highlight Solvonis’s strategic focus on addressing significant unmet needs in neuropsychiatric conditions, potentially enhancing its market position and offering substantial value to stakeholders.
More about Graft Polymer (UK) PLC
Solvonis Therapeutics plc is a clinical-stage biopharmaceutical company based in London and listed on the London Stock Exchange. The company is dedicated to developing innovative medicines targeting addiction and mental health disorders, with a focus on Alcohol Use Disorder (AUD) and Post-Traumatic Stress Disorder (PTSD). Solvonis is advancing a pipeline of repurposed and novel compounds, with three core R&D programs and a proprietary library of preclinical drug candidates.
Average Trading Volume: 14,324,719
Technical Sentiment Signal: Sell
Current Market Cap: £7.68M
For a thorough assessment of SVNS stock, go to TipRanks’ Stock Analysis page.